Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by
tissue esterase and not accumulates in the body for long periods of infusion. In addition,
similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic
effects through flumazenil. It has no injection pain and infusion syndrome compared with
propofol. There is no study to investigate overall postoperative functional recovery via
QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to
determine whether there is any difference in the quality of postoperative recovery between
propofol-based and remimazolam-based total intravenous anesthesia in female patients
undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the
frequency of complications are evaluated and compared between the two groups.